Peptide Based Infection Therapeutics Market are multipurpose tools designed to perform multiple tasks in aboratories that include sampling, mixing, and combining of liquid samples automatically. The automated liquid handling system facilitates elimination of sample contamination and reduces manual work of lab personnel by performing several laboratory tasks. These workstations are able to measure samples, add reagents, and ensure addition of liquids to bioassays in uniform pattern. The liquid handling workstations differ in volume of samples that can be handled and are available with variety of integrated software to maintain the footprint of the tasks carried out by these instruments.
Download PDF Brochure of Research Report:
Market players are introducing compact and user-friendly liquid handling workstations that can be operated in small and mid-level laboratories, in order sustain in the competitive market. For instance, in January 2014, Hamilton Robotics introduced NIMBUS PCR workstation at the annual Society for Laboratory Automation & Screening Conference. It is a compact and affordable workstation that enables fast and flexible assay set up. Moreover, Tecan Group Limited introduced Fluent Gx Automation workstation in February 2018 that is designed specifically to meet the stringent needs of clinical and regulated laboratories.
Peptide Based Infection Therapeutics Market Dynamics
Pharmaceutical companies are increasingly focusing on conducting number of research and development activities as well as outsourcing such activities to academic and private research institutes, which is increasing the number of new laboratory set-ups. This in turn increases demand for liquid handling systems, thereby fostering the market growth. Moreover, pharmaceutical companies are increasingly outsourcing their research to privately-based contract research organizations (CRO) to stay competitive in the exponentially growing pharmaceutical and biotechnology medicines sector. For instance, in May 2018, Ritter Pharmaceuticals, Inc.—a developer of novel therapeutic products entered into an agreement with Medpace—a clinical research organization (CRO)—to conduct the first of two pivotal Phase 3 clinical trials for RP-G28 among patients with lactose intolerance (LI). In October 2016, Sun Pharma—an India-based pharmaceutical company—announced plans to increase its research and development activities by investing in a new R&D unit at Madhya Pradesh, India.
Peptide Based Infection Therapeutics Market - Competitive Analysis
Major players operating in Peptide Based Infection Therapeutics Market are focused on new product launches. For instance, in October 2017, Qiagen launched a next-generation DNA testing automated workflow in collaboration with International Commission of Missing Persons (ICMP) for DNA identification through Qiagen’s instruments and consumables for DNA extraction, liquid handling, and others.
Major players operating in the market are Aurora Biomed, Inc., Hamilton Company, Tecan Group Ltd, Eppendorf AG, Qiagen N.V., Mettler-Toledo International Inc., Corning, Inc., Bio-Rad Laboratories Inc., PerkinElmer, Inc., Agilent Technologies, Inc., Danaher Corporation, and Thermo Fisher Scientific Inc.
Peptide Based Infection Therapeutics Market – Taxonomy
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• North America
• Asia Pacific
• Latin America
• Middle East
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]